Olympus Corp
TSE:7733

Watchlist Manager
Olympus Corp Logo
Olympus Corp
TSE:7733
Watchlist
Price: 2 458.5 JPY -0.79% Market Closed
Market Cap: 2.9T JPY
Have any thoughts about
Olympus Corp?
Write Note

Olympus Corp
Total Liabilities & Equity

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Olympus Corp
Total Liabilities & Equity Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Liabilities & Equity CAGR 3Y CAGR 5Y CAGR 10Y
Olympus Corp
TSE:7733
Total Liabilities & Equity
ÂĄ1.5T
CAGR 3-Years
10%
CAGR 5-Years
10%
CAGR 10-Years
4%
Terumo Corp
TSE:4543
Total Liabilities & Equity
ÂĄ1.8T
CAGR 3-Years
9%
CAGR 5-Years
9%
CAGR 10-Years
7%
Sysmex Corp
TSE:6869
Total Liabilities & Equity
ÂĄ618.1B
CAGR 3-Years
12%
CAGR 5-Years
11%
CAGR 10-Years
11%
Nihon Kohden Corp
TSE:6849
Total Liabilities & Equity
ÂĄ223.8B
CAGR 3-Years
7%
CAGR 5-Years
8%
CAGR 10-Years
6%
JEOL Ltd
TSE:6951
Total Liabilities & Equity
ÂĄ229.7B
CAGR 3-Years
11%
CAGR 5-Years
13%
CAGR 10-Years
8%
Fukuda Denshi Co Ltd
TSE:6960
Total Liabilities & Equity
ÂĄ206.1B
CAGR 3-Years
4%
CAGR 5-Years
5%
CAGR 10-Years
6%
No Stocks Found

Olympus Corp
Glance View

Market Cap
2.9T JPY
Industry
Health Care

Olympus Corp., a global leader in optical and digital precision technology, has carved a remarkable niche in the healthcare and life sciences sectors. Founded in Japan in 1919, the company initially focused on cameras and microscopes but has since evolved into a dominant player in the medical device arena, particularly known for its innovative imaging systems, endoscopy equipment, and surgical solutions. Olympus's commitment to enhancing healthcare outcomes is underscored by its significant investments in research and development, enabling the company to deliver cutting-edge solutions that improve patient care and empower healthcare professionals. With a strong presence in over 40 countries, Olympus not only addresses prevailing healthcare challenges but also actively participates in the global push toward minimally invasive procedures, thereby appealing to a growing segment of health-conscious patients and cost-sensitive healthcare systems. For investors, Olympus Corp. presents an intriguing opportunity characterized by resilient financial performance and strategic growth initiatives. The company has consistently demonstrated robust revenue generation, bolstered by its leadership in the endoscopy market, which accounts for a substantial portion of its sales. Furthermore, Olympus is strategically focused on expanding its product offerings through acquisitions and collaborations, reinforcing its commitment to innovation. The growing demand for minimally invasive surgeries, driven by advances in technology and patient preferences, positions Olympus favorably for future growth. With its solid foundation, continuous evolution, and commitment to sustainability, Olympus Corp. stands as a compelling investment option for those looking to align with a company dedicated to transforming healthcare and enhancing lives.

Intrinsic Value
2 702.13 JPY
Undervaluation 9%
Intrinsic Value
Price

See Also

What is Olympus Corp's Total Liabilities & Equity?
Total Liabilities & Equity
1.5T JPY

Based on the financial report for Jun 30, 2024, Olympus Corp's Total Liabilities & Equity amounts to 1.5T JPY.

What is Olympus Corp's Total Liabilities & Equity growth rate?
Total Liabilities & Equity CAGR 10Y
4%

Over the last year, the Total Liabilities & Equity growth was -10%. The average annual Total Liabilities & Equity growth rates for Olympus Corp have been 10% over the past three years , 10% over the past five years , and 4% over the past ten years .

Back to Top